Article
Oncology
Anett Baliko, Zsolt Szakacs, Bela Kajtar, Zsombor Ritter, Attila Gyenesei, Nelli Farkas, Laszlo Kereskai, Istvan Valyi-Nagy, Hussain Alizadeh, Laszlo Pajor
Summary: This study evaluates the application of immunohistochemistry and FISH molecular markers in the diagnosis and prognosis of DLBCL. The results show that IPI, BCL6 protein expression, and MIB-1 protein expression are independent predictors of survival outcomes in DLBCL. There is no difference in survival between GCB and non-GCB subtypes. These findings may improve prognostication in DLBCL and contribute to further research.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Yanjie Wang, Donglin Liu, Xudong Zhang, Mingzhi Zhang, Shenglei Li, Xiaoyan Feng, Meng Dong, Shanshan Ma, Siyu Qian, Zeyuan Wang, Yue Zhang, Pengyuan Wang, Shuhao Mei, Qingjiang Chen
Summary: The prognostic value of MYC protein expression and other biological parameters in bulky mass DLBCL patients were analyzed in this study. The results showed that MYC overexpression was associated with worse overall survival and progression-free survival, and consolidation radiotherapy improved outcomes for patients with bulky mass DLBCL.
Article
Pathology
Jin Roh, Dok Hyun Yoon, Yoon Kyoung Lee, Hyo-Kyung Pak, Sang-Yeob Kim, Jae Ho Han, Joon Seong Park, Seong Hyun Jeong, Yoon Seok Choi, Hyungwoo Cho, Cheolwon Suh, Jooryung Huh, Dae Ho Lee, Chan-Sik Park
Summary: This study proposes a refined method for diagnosing double-expresser lymphoma (DEL) by evaluating the concurrent expression of BCL2 and MYC at the single-cell level. The DUEL status determined by this method is shown to be an independent adverse prognostic variable and can be used to identify high-risk patients. This concept of DUEL may provide a better basis for both basic and clinical research for the development of new therapeutics.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2022)
Review
Medicine, General & Internal
Robert Ta, David Yang, Christian Hirt, Thomas Drago, Richard Flavin
Summary: DLBCL, the most common non-Hodgkin lymphoma, has been a focus of molecular subtyping efforts, evolving and integrating multiple methods for research.
Article
Oncology
Susanne Ghandili, Judith Dierlamm, Carsten Bokemeyer, Clara Marie von Bargen, Soeren Alexander Weidemann
Summary: This study aimed to investigate the expression of NTRK fusion proteins in diffuse large B-cell lymphoma (DLBCL). Immunohistochemistry (IHC) screening and FISH analysis were performed on a large cohort of DLBCL samples. The results showed no detectable NTRK immunostaining or FISH break apart. The study suggests that although NTRK fusion protein expression was not found in the DLBCL cohort, systematic screenings for NTRK fusions are still necessary to further understand their role in DLBCL and other lymphoma entities.
FRONTIERS IN ONCOLOGY
(2023)
Article
Genetics & Heredity
Haizhu Chen, Yan Qin, Peng Liu, Jianliang Yang, Lin Gui, Xiaohui He, Changgong Zhang, Shengyu Zhou, Liqiang Zhou, Sheng Yang, Yuankai Shi
Summary: This study found differences in genetic profiling and signaling pathways between the DEL group and the non-DEL group. The presence of DEL alone should not be considered as an adverse prognostic indicator, but BCL2 alteration may define a subset of patients with poor prognosis within DEL.
MOLECULAR DIAGNOSIS & THERAPY
(2023)
Article
Oncology
Masashi Miyaoka, Yara Yukie Kikuti, Joaquim Carreras, Atsushi Ito, Haruka Ikoma, Sakura Tomita, Hiroshi Kawada, Giovanna Roncador, Silvia Bea, Elias Campo, Naoya Nakamura
Summary: This study analyzed different subtypes of DLBCL using various methods and found that they have distinct genetic features and gene mutations. These findings are important for the comprehensive understanding of the molecular mechanisms of DLBCL and for providing personalized treatment strategies.
Article
Oncology
Qianhui Gu, Jing Li, Zhuolin Chen, Jie Zhang, Hui Shen, Xiaobing Miao, Ying Zhou, Xiaohong Xu, Song He
Summary: Recent studies have shown that PD-L2 expression is associated with clinicopathological features in DLBCL patients. Higher expression of PD-L2 is correlated with better prognosis and survival outcomes, indicating its potential as a therapeutic target in DLBCL.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Julie Devin, Tatiana Caneque, Yea-Lih Lin, Lucie Mondoulet, Jean-Luc Veyrune, Matthieu Abouladze, Elvira Garcia De Paco, Ouissem Karmous Gadacha, Guillaume Cartron, Philippe Pasero, Caroline Bret, Raphael Rodriguez, Jerome Moreaux
Summary: Diffuse large B-cell lymphoma (DLBCL) is a common hematological malignancy, and alterations in iron metabolism may be targeted for therapy. Iron score (IS), a gene expression-based risk score, can identify high-risk DLBCL patients who may benefit from targeting iron homeostasis. Ironomycin, a potential treatment for DLBCL, inhibits cell proliferation and induces cell death.
Article
Oncology
Dan Guo, Yuming Wang, Xunyao Wu, Yike Gao, Anqi Wang, Zixin Zhang, Kun Zhao, Xiaoxi Wang, Meiyu Liu, Yaran Zhang, Mei Li, Rui Chen, Jian Sun, Yan Zhang
Summary: Metabolites of tryptophan (Trp) metabolism in the tumor microenvironment play crucial immunosuppressive roles in diffuse large B-cell lymphoma (DLBCL) and natural killer/T-cell lymphoma (NK/TCL). The potential role of Trp metabolism was investigated in DLBCL and NK/TCL patients, and the expression of IDO1, IDO2, TDO2, and IL4I1 was analyzed. However, there was no significant difference in the positivity of these enzymes between PD-L1+ and PD-L1- tissue samples in NK/TCL patients.
Article
Pathology
Zaneta Swiderska-Chadaj, Konnie M. Hebeda, Michiel van den Brand, Geert Litjens
Summary: A deep learning algorithm was developed to detect MYC rearrangement in scanned histological slides, showing a high sensitivity of 0.93 and specificity of 0.52. This approach could allow for simple and fast prescreening, potentially saving around 34% of genetic tests.
Article
Radiology, Nuclear Medicine & Medical Imaging
Lars Kurch, Andreas Huettmann, Thomas W. Georgi, Jan Rekowski, Osama Sabri, Christine Schmitz, Regine Kluge, Ulrich Duehrsen, Dirk Hasenclever
Summary: In diffuse large B-cell lymphoma, continuous scales such as qPET and Delta SUVmax are more suitable for predicting treatment outcomes based on interim PET scans compared to the ordinal Deauville scale. The positive predictive value curves for qPET and Delta SUVmax were found to be similar, with both methods identifying less than 15% of patients as poor responders. The study suggests that continuous scales offer more accurate outcome predictions in this context.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Review
Oncology
Maria Huguet, Jose-Tomas Navarro, Jose Molto, Josep-Maria Ribera, Gustavo Tapia
Summary: Non-Hodgkin lymphoma (NHL) is a common HIV-related neoplasm, with diffuse large B-cell lymphoma (DLBCL) being the most common subtype. DLBCL in people with HIV presents with aggressive characteristics. The introduction of combined antiretroviral therapy (cART) and the use of cART with chemotherapy have significantly improved the prognosis for people with HIV and DLBCL, approaching that of the general population.
Article
Cell Biology
Eva A. M. Hesius, Lidia van Laar, Margriet Oosterveld, Annemiek B. van Spriel, Blanca Scheijen, Jan Willem Leeuwis, Henri A. M. Marres, Patricia J. T. A. Groenen, Wendy B. C. Stevens, Ellen van Der Spek, Adriaan J. C. van den Brule, Brigiet M. Hoevenaars, Konnie M. Hebeda, Michiel van den Brand
Summary: LBCL-IRF4 is a newly identified subtype of large B cell lymphoma in the 2017 revised WHO classification, initially reported in children. This study aimed to assess the frequency of IRF4 rearrangements in adult DLBCLs that need to be reclassified as LBCL-IRF4 using FISH. Among 238 DLBCL patients, six (including the index patient) were found to have IRF4 rearrangements, and their immunohistochemical profile was consistent with LBCL-IRF4. This study highlights the importance of considering LBCL-IRF4 in older patients and at different anatomical sites.
Article
Dentistry, Oral Surgery & Medicine
Shu Xia, Junqiu Yue, Xinming Chen, Yaying Hu, Fang Guo, Jiali Zhang
Summary: The study aimed to analyze the clinicopathological and molecular pathological features of diffuse large B-cell lymphoma in the oropharyngeal and maxillofacial region, with MYC protein expression being identified as an essential prognostic marker for patient outcomes. The study also found that immunohistochemical staining of MYC, BCL2, and BCL6 could not predict their gene rearrangements, indicating a disconnect between protein expression and gene translocation.
Article
Pathology
Lauren E. B. Lawrence, Atif Saleem, Malaya K. Sahoo, Susanna K. Tan, Benjamin A. Pinsky, Yasodha Natkunam, Christian A. Kunder, Henning Stehr, James L. Zehnder
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
(2020)
Article
Hematology
Michael S. Binkley, M. Shahzad Rauf, Sarah A. Milgrom, Chelsea C. Pinnix, Richard Tsang, Michael Dickinson, Andrea K. Ng, Kenneth B. Roberts, Sarah Gao, Alex Balogh, Umberto Ricardi, Mario Levis, Carla Casulo, Michael Stolten, Lena Specht, John P. Plastaras, Christopher Wright, Christopher R. Kelsey, Jessica L. Brady, N. George Mikhaeel, Bradford S. Hoppe, Stephanie A. Terezakis, Marco Picardi, Roberta Della Pepa, Youlia Kirova, Saad Akhtar, Irfan Maghfoor, Julie L. Koenig, Christopher Jackson, Erin Song, Shuchi Sehgal, Ranjana H. Advani, Yasodha Natkunam, Louis S. Constine, Hans T. Eich, Andrew Wirth, Richard T. Hoppe
Article
Medical Laboratory Technology
Joshua R. Menke, Michael A. Spinner, Yasodha Natkunam, Roger A. Warnke, Ranjana H. Advani, Dita A. Gratzinger
Summary: NLPHL can present as CD20-negative without prior rituximab therapy, and immunophenotyping is crucial for distinguishing NLPHL from lymphocyte-rich classic Hodgkin lymphoma. CD20-negative NLPHL may exhibit classic and variant histologic patterns and range of clinical behaviors, including potential large cell transformation.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
(2021)
Article
Hematology
Javier Raboso-Gallego, Ana Casado-Garcia, Xiaoyu Jiang, Marta Isidro-Hernandez, Andrew J. Gentles, Shuchun Zhao, Yaso Natkunam, Oscar Blanco, Veronica Dominguez, Belen Pintado, Diego Alonso-Lopez, Javier De las Rivas, Carolina Vicente-Duenas, Izidore S. Lossos, Isidro Sanchez-Garcia
Summary: The study shows that constitutive enforced expression of HGAL leads to DLBCL development, and this protein is mainly present in germinal center B lymphocytes.
Editorial Material
Oncology
Sheren Younes, Yasodha Natkunam
LEUKEMIA & LYMPHOMA
(2021)
Editorial Material
Hematology
Sheren Younes, Yasodha Natkunam
Review
Radiology, Nuclear Medicine & Medical Imaging
Hassan Aboughalia, Karen M. Chisholm, Ramesh S. Iyer
Summary: This case study describes a unique case of FNH in a 6-month-old girl with elevated AFP levels. Initially suspected to be hepatoblastoma due to the patient's age and AFP levels, histopathologic assessment confirmed the lesion to be typical for FNH. Further testing with hepatobiliary contrast agent was used to rule out the possibility of a collision or composite liver tumor.
Article
Oncology
Oscar Silva, Vivek Charu, Mark D. Ewalt, Ryan A. Metcalf, Shuchun Zhao, E. Mauricio Castellanos, Elizabeth Orellana, Yasodha Natkunam, Sandra Luna-Fineman
Summary: In Guatemala, children aged 0-6 with cHL have a high EBV expression rate of 97.5%, share similar immune regulatory mechanisms with adult cHL, and show increased CD8+ lymphocytes and tumor-associated macrophages in the tumor microenvironment. Despite high-risk disease in 25 patients, only four died from disease progression, relapse, or infection.
LEUKEMIA & LYMPHOMA
(2021)
Article
Pathology
Olga K. Weinberg, Karen M. Chisholm, Chi Young Ok, Yuri Fedoriw, Bartosz Grzywacz, Jason H. Kurzer, Emily F. Mason, Karen A. Moser, Siddharth Bhattacharya, Mina Xu, Daniel Babu, Kathryn Foucar, Wayne Tam, Adam Bagg, Attilio Orazi, Tracy George, Wei Wang, Sa A. Wang, Daniel A. Arber, Robert P. Hasserjian
Summary: NK-LL is a rare type of acute leukemia with distinct clinical presentation, immunophenotypic, and molecular characteristics compared to other types of acute leukemias. The study found that NK-LL patients are typically younger with higher white blood cell and platelet counts, and exhibit differences in certain immunophenotypic markers and gene mutations compared to other types of acute leukemias.
Review
Oncology
Sheren Younes, Rebecca B. Rojansky, Joshua R. Menke, Dita Gratzinger, Yasodha Natkunam
Summary: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma with unique biological behavior that requires careful differentiation from other lymphomas and their mimics. Recurrence and progression to different types of lymphomas are possible, highlighting the need for further research to personalize patient care.
Article
Pathology
Fei Fei, Kala Gnanasekaran Kiruthiga, Sheren Younes, Yasodha Natkunam
Summary: This study characterizes the clinicopathologic features of Epstein-Barr virus (EBV)-positive nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) at a single institution. The study found that EBV-positive NLPHL is rare and diagnostically challenging due to atypical immunophenotypic features.
Article
Cell Biology
Yasodha Natkunam, Daphne de Jong, Pedro Farinha, Philippe Gaulard, Wolfram Klapper, Andreas Rosenwald, Birgitta Sander, Reuben Tooze, Ranjana Advani, Catherine Burton, John G. Gribben, Marie-Jose Kersten, Eva Kimby, Georg Lenz, Thierry Molina, Franck Morschhauser, David Scott, Laurie Sehn, Wendy Stevens, Andrew Clear, Maryse Baia, Abdelmalek Habi, Mad-Helenie Elsensohn, Carole Langlois-Jacques, Delphine Maucort-Boulch, Maria Calaminici
Summary: Subclassification of large B cell lymphoma (LBCL) is challenging and conventional morphological parameters are not helpful. The use of fluorescence in-situ hybridisation (FISH) data is essential for accurate classification and prognostication of MYC-rearranged LBCL.
Article
Oncology
Karen M. M. Chisholm, Jenny Smith, Amy E. E. Heerema-McKenney, John K. K. Choi, Rhonda E. E. Ries, Betsy A. A. Hirsch, Susana C. C. Raimondi, Yi-Cheng Wang, Alice Dang, Todd A. A. Alonzo, Lillian Sung, Richard Aplenc, Alan S. S. Gamis, Soheil Meshinchi, Samir B. B. Kahwash
Summary: This study analyzed the different fusion genes and chromosomal abnormalities in pediatric acute myeloid leukemia (AMkL) and evaluated the 5-year event-free survival (EFS), overall survival (OS), and relapse rate in these subtypes. The results showed that CBFA2T3::GLIS2 and KMT2A rearrangements were associated with worse prognosis compared to other AMkL, while RBM15::MRTFA or AMkl-MRC subtypes had better outcomes. NUP98 fusion genes were associated with poor prognosis in the AAML1031 trial.
PEDIATRIC BLOOD & CANCER
(2023)
Article
Pathology
Sheren Younes, Shuchun Zhao, Sushma Bharadwaj, Alicia Palomino Mosquera, Diane Libert, Andrew Johnsrud, Robbie G. Majzner, David B. Miklos, Matthew J. Frank, Yasodha Natkunam
Summary: CD58 plays a crucial role in the activation and killing of target cells by T and NK cells. It is downregulated in a significant proportion of B-, T-, and NK-cell lymphomas, and its loss is associated with poor prognostic indicators in DLBCL and ALK and DUSP22 rearrangements in anaplastic large-cell lymphoma. However, it is not directly linked to overall or progression-free survival in any lymphoma subtype. CD58 status serves as an important biomarker for lymphoma patients who may benefit from next-generation T-cell-mediated therapies or other novel approaches to overcome immune escape.
Article
Pathology
Marie Das, Karen D. Tsuchiya, Sandra D. Bohling, Billy Davis, Samuel Hwang, Rebecca A. Gardner, Karen M. Chisholm
Summary: B-lymphoblastic leukemia/lymphoma (B-ALL/LBL) is a B-cell neoplasm with specific genetic/molecular abnormalities, requiring extensive testing for appropriate classification and treatment. This case report presents a patient with B-LBL harboring IGH::MYC, BCL2, BCL6 rearrangements, and TP53 inactivation. The use of a multimodal approach facilitated classification and selection of the therapeutic regimen.
PEDIATRIC AND DEVELOPMENTAL PATHOLOGY
(2023)